ecrin-mdr-crcClinical2022IPD Sharing (as of August 2023): NoGastro-Intestinal CancerGastrointestinal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsGastro-intestinal CancerIntestinal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2719035United States7Gastric and esophageal cancers (GEC)ECRIN MDRRecruitingfalsesFOLFOXIRI in Advanced Gastroesophageal Cancer, (SAGE)The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.2022-07-152719035NCT05332002